Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.440.02%
QQQ
715.040.02%
BTC/USD
77218.920.5457%
DIA
525.910.02%
GLD
398.290.12%
TLT
80.930.07%

Kura Oncology Inc

KURANASDAQ
Trade with Public
Trade with Public
$11.39
-0.18-1.56%
At close: Sep 11, 5:00 PM EST
$11.52
0.131.14%
After Hours: Sep 11, 6:12 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Kura Oncology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kura Oncology (KURA).

Price Target Range — 12 Quarters

Analyst Consensus — 16 Analysts

2S.Buy
11Buy
3Hold
Consensus RatingBuy# Analysts16Avg. Consensus PT$24Upside to Avg. PT+109.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 24, 2026CitizensReni J. BenjaminMaintainedMarket Outperform$24
Aug 13, 2026WedbushRobert DriscollPT RaiseOutperform$36→$38
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price Target

Citizens analyst Reni J. Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform and maintains $24 price target.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Kura Oncology, Raises Price Target to $38

Wedbush analyst Robert Driscoll maintains Kura Oncology (NASDAQ:KURA) with a Outperform and raises the price target from $36 to $38.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Kura Oncology, Maintains $36 Price Target

Wedbush analyst Robert Driscoll reiterates Kura Oncology (NASDAQ:KURA) with a Outperform and maintains $36 price target.
Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price Target

Citizens analyst Reni J. Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform and maintains $24 price target.
Benzinga Newsdesk

PRO
Lake Street Initiates Coverage On Kura Oncology with Buy Rating, Announces Price Target of $23

Lake Street analyst Daniel Brims initiates coverage on Kura Oncology (NASDAQ:KURA) with a Buy rating and announces Price Target of $23.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Kura Oncology, Lowers Price Target to $25

Mizuho analyst Mara Goldstein maintains Kura Oncology (NASDAQ:KURA) with a Outperform and lowers the price target from $30 to $25.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved